Update on safety incident of April 27, 2025 at Lyfius Pharma Private Limited, a wholly owned stepdown subsidiary of the Company

Fire or accident at a plantCapex & Operations View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹1181.80

prior close

₹1172.90

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.2%+0.3% vs market

Pharmaceuticals peers, median of 147sector+0.1%+0.4% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+1.8

15m

+1.7

30m

+2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.2+0.3+0.1+0.4

Next day

-3.2+0.3-3.5-0.0-3.2

-0.7+0.8-1.6+0.8-1.6

-2.7+0.6-3.3+0.3-3.0

-3.8+1.2-5.0+0.0-3.8

-3.2+0.8-4.1-0.6-2.7

-1.7+2.3-4.0+0.0-1.7

15d

-6.1+2.2-8.3-0.8-5.3

-4.8+4.0-8.9-0.6-4.2

-4.8+1.5-6.4+0.6-5.4

-12.8-0.6-12.2-2.9-9.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma has issued an update regarding a safety incident that occurred on April 27, 2025, at Lyfius Pharma Private Limited, which is its wholly owned stepdown subsidiary. The company is providing shareholders with information about the incident as part of its disclosure obligations. Lyfius Pharma operates as a stepdown subsidiary within the Aurobindo Pharma group structure. Details on operational impact, financial loss, injuries, or resumption of operations are not specified in the headline and would require the full filing for specifics.

Likely market impact

A safety incident at a subsidiary facility could affect production capacity and revenue if the plant is shut down for investigation, potentially weighing on the stock in the short term. Investors should watch for follow-up disclosures clarifying the extent of damage, regulatory action, and timeline for normal operations.